Hiroyuki Kobori

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/61441/publications.pdf

Version: 2024-02-01

174 papers	10,610 citations	26630 56 h-index	38395 95 g-index
174 all docs	174 docs citations	174 times ranked	6934 citing authors

#	Article	IF	Citations
1	Klotho supplementation attenuates blood pressure and albuminuria in murine model of IgA nephropathy. Journal of Hypertension, 2021, 39, 1567-1576.	0.5	4
2	Klotho supplementation ameliorates blood pressure and renal function in DBA/2-pcy mice, a model of polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2020, 318, F557-F564.	2.7	22
3	Interactions between Host PPARs and Gut Microbiota in Health and Disease. International Journal of Molecular Sciences, 2019, 20, 387.	4.1	46
4	Melatonin in chronic kidney disease: a promising chronotherapy targeting the intrarenal reninâ€“angiotensin system. Hypertension Research, 2019, 42, 920-923.	2.7	22
5	Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertension Research, 2019, 42, 769-778.	2.7	28
6	Klotho protein supplementation reduces blood pressure and renal hypertrophy in db/db mice, a model of type 2 diabetes. Acta Physiologica, 2019, 225, e13190.	3.8	53
7	Independent regulation of reninâ€“angiotensinâ€“aldosterone system in the kidney. Clinical and Experimental Nephrology, 2018, 22, 1231-1239.	1.6	87
8	PPARÎ³ activation mitigates glucocorticoid receptorâ€induced excessive lipolysis in adipocytes via homeostatic crosstalk. Journal of Cellular Biochemistry, 2018, 119, 4627-4635.	2.6	17
9	Effect of a SGLT2 inhibitor on the systemic and intrarenal reninâ€“angiotensin system in subtotally nephrectomized rats. Journal of Pharmacological Sciences, 2018, 137, 220-223.	2.5	45
10	Klotho Ameliorates Medullary Fibrosis and Pressure Natriuresis in Hypertensive Rat Kidneys. Hypertension, 2018, 72, 1151-1159.	2.7	33
11	Add-On Effect of Angiotensin Receptor Blockade (Candesartan) on Clinical Remission in Active IgA Nephropathy Patients Treated with Steroid Pulse Therapy and Tonsillectomy: a Randomized, Parallel-Group Comparison Trial. Kidney and Blood Pressure Research, 2018, 43, 780-792.	2.0	6
12	Altered Circadian Timing System-Mediated Non-Dipping Pattern of Blood Pressure and Associated Cardiovascular Disorders in Metabolic and Kidney Diseases. International Journal of Molecular Sciences, 2018, 19, 400.	4.1	26
13	Antiproliferative effects of polyclonal antibody against (pro) renin receptor in pancreatic ductal adenocarcinoma cells. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-29.	0.0	0
14	Effects of Olmesartan and Azilsartan on Albuminuria and the Intrarenal Renin-Angiotensin System. World Journal of Research and Review, 2018, 6, 7-10.	0.1	1
15	Klotho suppresses the renin-angiotensin system in adriamycin nephropathy. Nephrology Dialysis Transplantation, 2017, 32, gfw340.	0.7	23
16	Intrarenal renin-angiotensin system activation in end-stage renal disease. Hypertension Research, 2017, 40, 351-352.	2.7	8
17	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients with Type 2 Diabetes. Journal of Investigative Medicine, 2017, 65, 1057-1061.	1.6	41
18	High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5. PLoS ONE, 2017, 12, e0185600.	2.5	19

#	Article	IF	Citations
19	Sodium balance, circadian BP rhythm, heart rate variability, and intrarenal renin-angiotensin-aldosterone and dopaminergic systems in acute phase of ARB therapy. Physiological Reports, 2017, 5, e13309.	1.7	10
20	Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients. International Journal of Molecular Sciences, 2016, 17, 1800.	4.1	5
21	Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0164936.	2.5	11
22	Quantification of intact plasma AGT consisting of oxidized and reduced conformations using a modified ELISA. American Journal of Physiology - Renal Physiology, 2016, 311, F1211-F1216.	2.7	7
23	Addition of hydrochlorothiazide to angiotensin receptor blocker therapy can achieve a lower sodium balance with no acceleration of intrarenal renin angiotensin system in patients with chronic kidney disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031665203.	1.7	6
24	(Pro)renin receptor is crucial for Wnt/Î²-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Scientific Reports, 2015, 5, 8854.	3.3	52
25	Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes. Journal of Diabetes Research, 2015, 2015, 1-7.	2.3	6
26	Changes in urinary angiotensinogen posttreatment in pediatric IgA nephropathy patients. Pediatric Nephrology, 2015, 30, 975-982.	1.7	10
27	Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney. European Journal of Pharmacology, 2015, 756, 85-91.	3.5	12
28	Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical and Experimental Nephrology, 2015, 19, 1098-1106.	1.6	49
29	Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertension Research, 2015, 38, 237-243.	2.7	28
30	Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia, 2015, 58, 2885-2898.	6.3	49
31	Nitrosonifedipine Ameliorates the Progression of Type 2 Diabetic Nephropathy by Exerting Antioxidative Effects. PLoS ONE, 2014, 9, e86335.	2.5	10
32	Regression of Glomerular and Tubulointerstitial Injuries by Dietary Salt Reduction with Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker in Dahl Salt-Sensitive Rats. PLoS ONE, 2014, 9, e107853.	2.5	16
33	Detailed Localization of Augmented Angiotensinogen mRNA and Protein in Proximal Tubule Segments of Diabetic Kidneys in Rats and Humans. International Journal of Biological Sciences, 2014, 10, 530-542.	6.4	12
34	Serum soluble (pro)renin receptor levels in patients with essential hypertension. Hypertension Research, 2014, 37, 642-648.	2.7	61
35	Deletion of the angiotensin II type 1 receptorâ€“associated protein enhances renal sodium reabsorption and exacerbates angiotensin IIâ€“mediated hypertension. Kidney International, 2014, 86, 570-581.	5.2	47
36	ROCK/NF-ÎºB axis-dependent augmentation of angiotensinogen by angiotensin II in primary-cultured preglomerular vascular smooth muscle cells. American Journal of Physiology - Renal Physiology, 2014, 306, F608-F618.	2.7	14

#	Article	IF	Citations
37	Circadian rhythm of plasma and urinary angiotensinogen in healthy volunteers and in patients with chronic kidney disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 505-508.	1.7	15
38	Liver-specific angiotensinogen suppression: an old yet novel target for blood pressure control through RAS inhibition?. Hypertension Research, 2014, 37, 393-394.	2.7	2
39	Renoprotective Effects of Direct Renin Inhibition in Glomerulonephritis. American Journal of the Medical Sciences, 2014, 348, 306-314.	1.1	11
40	The natriuretic effect of angiotensin receptor blockers is not attributable to blood pressure reduction during the previous night, but to inhibition of tubular sodium reabsorption. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 316-318.	1.7	3
41	High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1/2-dependent pathway. Hypertension Research, 2014, 37, 13-18.	2.7	28
42	Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. Journal of Diabetes and Its Complications, 2014, 28, 604-611.	2.3	100
43	Direct Evidence for Intrarenal Chymase-Dependent Angiotensin II Formation on the Diabetic Renal Microvasculature. Hypertension, 2013, 61, 465-471.	2.7	30
44	Aldosterone aggravates glucose intolerance induced by high fructose. European Journal of Pharmacology, 2013, 720, 63-68.	3.5	17
45	Oxidative Stress/Angiotensinogen/Renin-Angiotensin System Axis in Patients with Diabetic Nephropathy. International Journal of Molecular Sciences, 2013, 14, 23045-23062.	4.1	58
46	Activation of the renin-angiotensin system by a low-salt diet does not augment intratubular angiotensinogen and angiotensin II in rats. American Journal of Physiology - Renal Physiology, 2013, 304, F505-F514.	2.7	47
47	Enhanced Angiotensin Receptor-Associated Protein in Renal Tubule Suppresses Angiotensin-Dependent Hypertension. Hypertension, 2013, 61, 1203-1210.	2.7	45
48	The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertension Research, 2013, 36, 262-269.	2.7	24
49	Effects of Angiotensin II AT1^|^ndash;Receptor Blockade on High Fat Diet^|^ndash;Induced Vascular Oxidative Stress and Endothelial Dysfunction in Dahl Salt-Sensitive Rats. Journal of Pharmacological Sciences, 2013, 121, 95-102.	2.5	16
50	Roles of Na+/H+ Exchanger Type 1 and Intracellular pH in Angiotensin II-Induced Reactive Oxygen Species Generation and Podocyte Apoptosis. Journal of Pharmacological Sciences, 2013, 122, 176-183.	2.5	16
51	Angiotensin-Converting Enzyme Inhibitor Does Not Suppress Renal Angiotensin II Levels in Angiotensin I^|^ndash;Infused Rats. Journal of Pharmacological Sciences, 2013, 122, 103-108.	2.5	4
52	Cardinal Role of the Intrarenal Renin-Angiotensin System in the Pathogenesis of Diabetic Nephropathy. Journal of Investigative Medicine, 2013, 61, 256-264.	1.6	53
53	Reninâ€“Angiotensin System. , 2013, , 1499-1506.		0
54	Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice. PLoS ONE, 2013, 8, e82082.	2.5	6

#	Article	IF	Citations
55	Angiotensin II Blockade and Renal Protection. Current Pharmaceutical Design, 2013, 19, 3033-3042.	1.9	67
56	Abstract 566: Angiotensin II Promotes Proliferation and Fibrosis in Parietal Epithelial Cells Contributing to the Development of Crescentic Glomerulonephritis. Hypertension, 2013, 62, .	2.7	0
57	Abstract 195: Circadian Rhythm of Plasma and Urinary Angiotensinogen in Patients with Chronic Kidney Disease. Hypertension, 2013, 62, .	2.7	1
58	The Establishment of a Primary Culture System of Proximal Tubule Segments Using Specific Markers from Normal Mouse Kidneys. International Journal of Molecular Sciences, 2012, 13, 5098-5111.	4.1	37
59	AT₁ receptor-mediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension. American Journal of Physiology - Renal Physiology, 2012, 302, F85-F94.	2.7	70
60	Early Treatment With Olmesartan Prevents Juxtamedullary Glomerular Podocyte Injury and the Onset of Microalbuminuria in Type 2 Diabetic Rats. American Journal of Hypertension, 2012, 25, 604-611.	2.0	38
61	Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2012, 3, 318-324.	2.4	41
62	Regulation of a novel angiotensin II precursor, proangiotensin-12, in the tissues by blockade of the reninâ€“angiotensin system. Hypertension Research, 2012, 35, 153-154.	2.7	2
63	Interferonâ€Î³ biphasically regulates angiotensinogen expressionviaa JAKâ€STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. FASEB Journal, 2012, 26, 1821-1830.	0.5	63
64	Liver Angiotensinogen Is the Primary Source of Renal Angiotensin II. Journal of the American Society of Nephrology: JASN, 2012, 23, 1181-1189.	6.1	220
65	Brain-Targeted (Pro)renin Receptor Knockdown Attenuates Angiotensin IIâ€“Dependent Hypertension. Hypertension, 2012, 59, 1188-1194.	2.7	89
66	Hypercontrols in Genotype-Phenotype Analysis Reveal Ancestral Haplotypes Associated With Essential Hypertension. Hypertension, 2012, 59, 847-853.	2.7	15
67	Renal Sympathetic Denervation Suppresses De Novo Podocyte Injury and Albuminuria in Rats With Aortic Regurgitation. Circulation, 2012, 125, 1402-1413.	1.6	114
68	Aldosterone Does Not Contribute to Renal p21 Expression During the Development of Angiotensin II-Induced Hypertension in Mice. American Journal of Hypertension, 2012, 25, 354-358.	2.0	5
69	Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3176-3181.	0.7	63
70	Divergent localization of angiotensinogen mRNA and protein in proximal tubule segments of normal rat kidney. Journal of Hypertension, 2012, 30, 2365-2372.	0.5	16
71	Proximal tubular angiotensinogen in renal biopsy suggests nondipper BP rhythm accompanied by enhanced tubular sodium reabsorption. Journal of Hypertension, 2012, 30, 1453-1459.	0.5	26
72	Important Aspects of Urine Sampling for Angiotensinogen Measurement: Time and Preservation Conditions in Healthy Individuals. Tohoku Journal of Experimental Medicine, 2012, 228, 333-339.	1.2	7

#	Article	IF	Citations
73	N-type Calcium Channel Inhibition With Cilnidipine Elicits Glomerular Podocyte Protection Independent of Sympathetic Nerve Inhibition. Journal of Pharmacological Sciences, 2012, 119, 359-367.	2.5	13
74	Urinary Angiotensinogen as a Novel Early Biomarker of Intrarenal Renin^|^ndash;Angiotensin System Activation in Experimental Type 1 Diabetes. Journal of Pharmacological Sciences, 2012, 119, 314-323.	2.5	46
75	Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan. Journal of Pharmacological Sciences, 2012, 119, 131-138.	2.5	15
76	Multiphoton Imaging of the Glomerular Permeability of Angiotensinogen. Journal of the American Society of Nephrology: JASN, 2012, 23, 1847-1856.	6.1	108
77	Aldosterone induces p21â€regulated apoptosis via increased synthesis and secretion of tumour necrosis factorâ€Î± in human proximal tubular cells. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 858-863.	1.9	14
78	Sexual Dimorphism in Urinary Angiotensinogen Excretion During Chronic Angiotensin IIâ^'Salt Hypertension. Gender Medicine, 2012, 9, 207-218.	1.4	23
79	Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease. Pflugers Archiv European Journal of Physiology, 2012, 465, 3-12.	2.8	33
80	The Link Between the Renin-Angiotensin-Aldosterone System and Renal Injury in Obesity and the Metabolic Syndrome. Current Hypertension Reports, 2012, 14, 160-169.	3.5	114
81	Oxidative Stress-Induced Glomerular Mineralocorticoid Receptor Activation Limits the Benefit of Salt Reduction in Dahl Salt-Sensitive Rats. PLoS ONE, 2012, 7, e41896.	2.5	23
82	Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-Î± in human proximal tubular cells. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 858-63.	1.9	9
83	Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Current Opinion in Pharmacology, 2011, 11, 180-186.	3.5	149
84	Salt-induced renal injury in SHRs is mediated by AT1 receptor activation. Journal of Hypertension, 2011, 29, 716-723.	0.5	58
85	Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. Journal of Hypertension, 2011, 29, 290-298.	0.5	48
86	Effect of Efonidipine on TGF-Î²1â€“Induced Cardiac Fibrosis Through Smad2-Dependent Pathway in Rat Cardiac Fibroblasts. Journal of Pharmacological Sciences, 2011, 117, 98-105.	2.5	41
87	Variants and Haplotypes in Angiotensinogen Gene Are Associated With Plasmatic Angiotensinogen Level in Mexican Population. American Journal of the Medical Sciences, 2011, 342, 205-211.	1.1	19
88	Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2011, 26, 170-177.	0.7	118
89	Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrology Dialysis Transplantation, 2011, 26, 800-813.	0.7	153
90	Relationship Between Urinary Angiotensinogen and Salt Sensitivity of Blood Pressure in Patients With IgA Nephropathy. Hypertension, 2011, 58, 205-211.	2.7	42

#	Article	IF	Citations
91	Blockade of AT1 Receptors Protects the Blood-Brain Barrier and Improves Cognition in Dahl Salt-Sensitive Hypertensive Rats. American Journal of Hypertension, 2011, 24, 362-368.	2.0	86
92	Intratubular Renin-Angiotensin System in Hypertension. Hypertension, 2011, 57, 355-362.	2.7	199
93	Contribution of a Nuclear Factor-Î¹B Binding Site to Human Angiotensinogen Promoter Activity in Renal Proximal Tubular Cells. Hypertension, 2011, 57, 608-613.	2.7	26
94	Addition of Angiotensin II Type 1 Receptor Blocker to CCR2 Antagonist Markedly Attenuates Crescentic Glomerulonephritis. Hypertension, 2011, 57, 586-593.	2.7	44
95	Rho-kinase/nuclear factor-Î²Î²/angiotensinogen axis in angiotensin II-induced renal injury. Hypertension Research, 2011, 34, 976-979.	2.7	7
96	Angiotensin II Shifts Insulin Signaling Into Vascular Remodeling From Glucose Metabolism in Vascular Smooth Muscle Cells. American Journal of Hypertension, 2011, 24, 1149-1155.	2.0	15
97	Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1â€“7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. American Journal of Physiology - Renal Physiology, 2011, 300, F749-F755.	2.7	61
98	Increased renin excretion is associated with augmented urinary angiotensin II levels in chronic angiotensin II-infused hypertensive rats. American Journal of Physiology - Renal Physiology, 2011, 301, F1195-F1201.	2.7	55
99	Renin-Angiotensin System in the Kidney and Oxidative Stress: Local Renin-Angiotensin-Aldosterone System and NADPH Oxidase-Dependent Oxidative Stress in the Kidney. , 2011, , 71-91.		2
100	Angiotensinogen Expression Is Enhanced in the Progression of Glomerular Disease. International Journal of Clinical Medicine, 2011, 02, 378-387.	0.2	21
101	Short-Term Calorie Restriction in Early Life Attenuates the Development of Proteinuria but Not Glucose Intolerance in Type 2 Diabetic OLETF Rats. Isrn Endocrinology, 2011, 2011, 1-7.	2.0	8
102	Urinary Angiotensinogen as a Novel Biomarker of Intrarenal Renin-Angiotensin System in Chronic Kidney Disease. International Review of Thrombosis, 2011, 6, 108-116.	1.0	24
103	Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. Journal of Hypertension, 2010, 28, 1034-1043.	0.5	41
104	Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. Journal of Hypertension, 2010, 28, 2289-2298.	0.5	39
105	Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study). Journal of Hypertension, 2010, 28, 1422-1428.	0.5	68
106	Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Journal of Applied Physiology, 2010, 109, 2003-2014.	2.5	3
107	Enhanced Urinary Angiotensinogen Excretion in Cyp1a1-Ren2 Transgenic Rats With Inducible ANG II-Dependent Malignant Hypertension. American Journal of the Medical Sciences, 2010, 340, 389-394.	1.1	16
108	Adipose tissueâ€“specific dysregulation of angiotensinogen by oxidative stress in obesity. Metabolism: Clinical and Experimental, 2010, 59, 1241-1251.	3.4	30

#	Article	IF	Citations
109	Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen speciesâ€"ERK/JNK pathways. Hypertension Research, 2010, 33, 1174-1181.	2.7	55
110	Adipose Tissueâ€"Specific Regulation of Angiotensinogen in Obese Humans and Mice: Impact of Nutritional Status and Adipocyte Hypertrophy. American Journal of Hypertension, 2010, 23, 425-431.	2.0	94
111	Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 1072-1080.	2.5	44
112	Systemic candesartan reduces brain angiotensin II via downregulation of brain reninâ€"angiotensin system. Hypertension Research, 2010, 33, 161-164.	2.7	34
113	Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition. American Journal of Physiology - Renal Physiology, 2010, 298, F150-F157.	2.7	62
114	Major role for ACE-independent intrarenal ANG II formation in type II diabetes. American Journal of Physiology - Renal Physiology, 2010, 298, F37-F48.	2.7	81
115	Tumor necrosis factor-Î± suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells. American Journal of Physiology - Cell Physiology, 2010, 299, C750-C759.	4.6	37
116	Urinary Angiotensinogen Accurately Reflects Intrarenal Renin-Angiotensin System Activity. American Journal of Nephrology, 2010, 31, 318-325.	3.1	85
117	Angiotensin II-induced reduction in body mass is Ang II receptor mediated in association with elevated corticosterone. Growth Hormone and IGF Research, 2010, 20, 282-288.	1.1	11
118	Urinary Renin Excretion is augmented in Chronic Angiotensin IIâ€infused Sprague–Dawley Hypertensive Rats. FASEB Journal, 2010, 24, 786.18.	0.5	0
119	Increased Urinary Angiotensinogen Is Precedent to Increased Urinary Albumin in Patients With Type 1 Diabetes. American Journal of the Medical Sciences, 2009, 338, 478-480.	1.1	110
120	Angiotensin II and hypertonicity modulate proximal tubular aquaporin 1 expression. American Journal of Physiology - Renal Physiology, 2009, 297, F1575-F1586.	2.7	42
121	Angiotensin-Converting Enzymeâ€"Derived Angiotensin II Formation During Angiotensin IIâ€"Induced Hypertension. Hypertension, 2009, 53, 351-355.	2.7	50
122	Urinary Angiotensinogen as a Novel Biomarker of the Intrarenal Renin-Angiotensin System Status in Hypertensive Patients. Hypertension, 2009, 53, 344-350.	2.7	188
123	ACTIVATION OF REACTIVE OXYGEN SPECIES AND THE RENINâ€"ANGIOTENSIN SYSTEM IN IgA NEPHROPATHY MODEL MICE. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 509-515.	1.9	28
124	ROLE OF ACTIVATED INTRARENAL REACTIVE OXYGEN SPECIES AND RENINâ€"ANGIOTENSIN SYSTEM IN IgA NEPHROPATHY MODEL MICE. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 750-755.	1.9	40
125	IL-6 augments angiotensinogen in primary cultured renal proximal tubular cells. Molecular and Cellular Endocrinology, 2009, 311, 24-31.	3.2	49
126	Collecting duct renin: a major player in angiotensin IIâ€"dependent hypertension. Journal of the American Society of Hypertension, 2009, 3, 96-104.	2.3	68

#	Article	IF	Citations
127	Contribution of Chymase-Dependent Angiotensin II Formation to the Progression of Tubulointerstitial Fibrosis in Obstructed Kidneys in Hamsters. Journal of Pharmacological Sciences, 2009, 111, 82-90.	2.5	28
128	Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy. Biomarker Insights, 2009, 4, BMI.S2733.	2.5	72
129	The growth factor midkine regulates the renin-angiotensin system in mice. Journal of Clinical Investigation, 2009, 119, 1616-1625.	8.2	76
130	Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy. Pediatric Nephrology, 2008, 23, 1257-1267.	1.7	45
131	SEQUENTIAL ACTIVATION OF THE REACTIVE OXYGEN SPECIES/ANGIOTENSINOGEN/RENINâ€“ANGIOTENSIN SYSTEM AXIS IN RENAL INJURY OF TYPE 2 DIABETIC RATS. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 922-927.	1.9	69
132	Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. Journal of the American Society of Hypertension, 2008, 2, 349-354.	2.3	130
133	Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. American Journal of Physiology - Renal Physiology, 2008, 294, F161-F169.	2.7	45
134	Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. American Journal of Physiology - Renal Physiology, 2008, 295, F772-F779.	2.7	102
135	Collecting Duct Renin Is Upregulated in Both Kidneys of 2-Kidney, 1-Clip Goldblatt Hypertensive Rats. Hypertension, 2008, 51, 1590-1596.	2.7	103
136	Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. American Journal of Physiology - Renal Physiology, 2008, 295, F283-F289.	2.7	62
137	Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA. American Journal of Physiology - Renal Physiology, 2008, 294, F1257-F1263.	2.7	59
138	Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. Journal of Hypertension, 2008, 26, 1849-1859.	0.5	47
139	Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. American Journal of Physiology - Renal Physiology, 2007, 292, F330-F339.	2.7	141
140	Crucial role of Rho-nuclear factor-Î²B axis in angiotensin II-induced renal injury. American Journal of Physiology - Renal Physiology, 2007, 293, F100-F109.	2.7	39
141	Novel sandwich ELISA for human angiotensinogen. American Journal of Physiology - Renal Physiology, 2007, 293, F956-F960.	2.7	118
142	Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. American Journal of Physiology - Renal Physiology, 2007, 293, F938-F945.	2.7	103
143	Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochemical and Biophysical Research Communications, 2007, 358, 156-163.	2.1	79
144	The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. Pharmacological Reviews, 2007, 59, 251-287.	16.0	1,082

#	Article	IF	Citations
145	The Intrarenal Renin-Angiotensin System. , 2007, , 3-22.		4
146	Intrarenal Oxidative Stress and Augmented Angiotensinogen are Precedent to Renal Injury in Zucker Diabetic Fatty Rats. International Journal of Biological Sciences, 2007, 3, 40-46.	6.4	47
147	Young Scholars Award Lecture: Intratubular Angiotensinogen in Hypertension and Kidney Diseases. American Journal of Hypertension, 2006, 19, 541-550.	2.0	93
148	Quantification of human angiotensinogen by a novel sandwich ELISA. Peptides, 2006, 27, 3000-3002.	2.4	20
149	Intratubular Renin-Angiotensin System in Hypertension. Current Hypertension Reviews, 2006, 2, 151-157.	0.9	6
150	New Generation Calcium Channel Blockers in Hypertensive Treatment. Current Hypertension Reviews, 2006, 2, 103-111.	0.9	31
151	Renal Renin-Angiotensin System. , 2006, , 1235-1242.		6
152	Regulation of Renin in JGA and Tubules in Hypertension. , 2006, , 45-59.		3
153	AT₁receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. American Journal of Physiology - Renal Physiology, 2005, 289, F632-F637.	2.7	122
154	Enhanced Intrarenal Angiotensinogen Contributes to Early Renal Injury in Spontaneously Hypertensive Rats. Journal of the American Society of Nephrology: JASN, 2005, 16, 2073-2080.	6.1	155
155	Temporary Angiotensin II Blockade at the Prediabetic Stage Attenuates the Development of Renal Injury in Type 2 Diabetic Rats. Journal of the American Society of Nephrology: JASN, 2005, 16, 703-711.	6.1	136
156	Olmesartan Improves Endothelin-Induced Hypertension and Oxidative Stress in Rats. Hypertension Research, 2004, 27, 493-500.	2.7	42
157	Renal Renin-Angiotensin System. , 2004, 143, 117-130.		57
158	Enhancement of Collecting Duct Renin in Angiotensin IIâ€“Dependent Hypertensive Rats. Hypertension, 2004, 44, 223-229.	2.7	210
159	AT ₁ Receptor Mediated Augmentation of Intrarenal Angiotensinogen in Angiotensin II-Dependent Hypertension. Hypertension, 2004, 43, 1126-1132.	2.7	162
160	Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. Kidney International, 2004, 65, 972-981.	5.2	86
161	Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats. Biochemical and Biophysical Research Communications, 2004, 315, 746-750.	2.1	74
162	Intrarenal angiotensin II and hypertension. Current Hypertension Reports, 2003, 5, 135-143.	3.5	84

#	Article	IF	Citations
163	Enhancement of Intrarenal Angiotensinogen in Dahl Salt-Sensitive Rats on High Salt Diet. Hypertension, 2003, 41, 592-597.	2.7	239
164	Role of Angiotensin II and Reactive Oxygen Species in Cyclosporine Aâ€“Dependent Hypertension. Hypertension, 2003, 42, 754-760.	2.7	101
165	Urinary Angiotensinogen as an Indicator of Intrarenal Angiotensin Status in Hypertension. Hypertension, 2003, 41, 42-49.	2.7	225
166	Regulation of Intrarenal Angiotensin II in Hypertension. Hypertension, 2002, 39, 316-322.	2.7	344
167	Intrarenal AT₁receptor and ACE binding in ANG II-induced hypertensive rats. American Journal of Physiology - Renal Physiology, 2002, 282, F19-F25.	2.7	105
168	Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney International, 2002, 61, 579-585.	5.2	231
169	Enhancement of Angiotensinogen Expression in Angiotensin IIâ€“Dependent Hypertension. Hypertension, 2001, 37, 1329-1335.	2.7	178
170	Thyroid Hormone Stimulates Renin Gene Expression Through the Thyroid Hormone Response Element. Hypertension, 2001, 37, 99-104.	2.7	34
171	Review: Intrarenal angiotensin II levels in normal and hypertensive states. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S176-S184.	1.7	56
172	Expression of Angiotensinogen mRNA and Protein in Angiotensin II-Dependent Hypertension. Journal of the American Society of Nephrology: JASN, 2001, 12, 431-439.	6.1	219
173	Increased activity and expression of Ca²⁺-dependent NOS in renal cortex of ANG II-infused hypertensive rats. American Journal of Physiology - Renal Physiology, 1999, 277, F797-F804.	2.7	30
174	Differential effects of thyroid hormone on renin secretion, content, and mRNA in juxtaglomerular cells. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E224-E231.	3.5	26